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Abstract 
Objective: The incidence of gastric cancer is high in Chinese Tibetan. This study aimed to identify the differentially 
expressed microRNAs (miRNAs) and further explore their potential roles in Tibetan with gastric cancer so as to predict 
potential therapeutic targets.
Methods: A total of 10 Tibetan patients (male:female = 6:4) with gastric cancer were enrolled for isolation of 
matched gastric cancer and adjacent non-cancerous tissue samples. Affymetrix GeneChip microRNA 3.0 Array was 
employed for detection of miRNA expression in samples. Differential expression analysis between two sample groups 
was analyzed using Limma package. Then, MultiMiR package was used to predict targets for miRNAs. Following, the 
target genes were put into DAVID (Database for Annotation, Visualization and Integrated Discovery) to identify the 
significant pathways of miRNAs.
Results: Using Limma package in R, a total of 27 differentially expressed miRNAs were screened out in gastric cancer, 
including 25 down-regulated (e.g. hsa-miR-148a-3p, hsa-miR-148b-3p and hsa-miR-363-3p) and 2 up-regulated miR-
NAs. According to multiMiR package, a number of 1445 target genes (e.g. Wnt1, KLF4 and S1PR1) of 13 differentially 
expressed miRNAs were screened out. Among those miRNAs, hsa-miR-148a-3p, hsa-miR-148b-3p and hsa-miR-363-3p 
were identified with the most target genes. Furthermore, three miRNAs were significantly enriched in numerous com-
mon cancer-related pathways, including “Wnt signaling pathway”, “MAPK signaling pathway” and “Jak-STAT signaling 
pathway”.
Conclusions: The present study identified a downregulation and enrichment in cancer-related pathways of hsa-miR-
148a-3p, hsa-miR-148b-3p and hsa-miR-363-3p in Tibetan with gastric cancer, which can be suggested as therapeutic 
targets.
Keywords: Gastric cancer, miRNA microarray, Differentially expressed miRNAs, Enrichment analysis, Network of 
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Background
Gastric cancer is one of the most common malignan-
cies worldwide. Although incidence and mortality of 
gastric cancer has been dramatically decreased over 
the last decades worldwide, the declines are becoming 
less remarkable in some countries [1]. The main rea-
son may be that there are limited treatment options and 
patients in advanced stages could not be cured by surgi-
cal removal [2]. Moreover, 5-year survival rates of gastric 
cancer are decreased with gastric cancer progression [3] 
and metastatic stage could lead to poor outcomes [4]. In 
Chinese Qinghai, the Tibetan ethnic group has a higher 
incidence of gastric cancer than the Han ethnic group 
[5]. Thus, there is an urgent need to develop effective 
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treatments to improve diagnosis and reduce burden of 
gastric cancer in gastric cancer-infected Tibetan.
A number of key genes with abnormal expression in the 
progression of gastric cancer have been screened out. For 
example, the over-expression of SPAG9 (sperm associ-
ated antigen 9) correlates with poor prognosis and leads 
to gastric cancer invasion and chemo-resistance [6]. In 
terms of Tibetan with gastric cancer, the expression pat-
tern of tumor-associated antigen MG(7)-Ag is abnormal 
and it can be used as a reliable marker to predict gastric 
cancer at early stage [7]. The polymorphisms of prostate 
stem cell antigen gene are also associated with gastric 
cancer in Tibetans [8]. Therefore, the identification of key 
genes can improve diagnosis and management of gastric 
cancer in Tibetan.
MicroRNAs (miRNAs) are a group of small non-cod-
ing RNAs that have important roles in the development 
of numerous cancer types, through down-regulation of 
the target genes [9, 10]. Multiple miRNAs are expressed 
aberrantly and are involved in the progression and prog-
nosis of gastric cancer [11]. Therefore, investigating role 
of miRNAs in gastric cancer could provide new insight 
into the biological mechanism of this disease. Report-
edly, miR-21 is up-regulated in gastric cancer and its 
dysregulation can enhance cell proliferation, invasion 
and migration through down-regulating a set of tumor 
suppressor genes, such as RECK (reversion-inducing-
cysteine-rich protein with kazal motifs) [12]. In addition, 
miR-544a could activate the Wnt signaling pathway by 
stabilizing the β-catenin in nucleus and its inhibition may 
be a therapeutic method for metastatic gastric cancer 
[13]. However, the research on miRNAs in gastric cancer 
in Tibetan is really rare and therefore, the exploration of 
miRNAs in the progression of gastric cancer in Tibetan is 
of great significance.
In the present study, the paired cancerous and adja-
cent non-cancerous tissue samples were collected from 
10 patients with gastric cancer, and further conducted 
for miRNA expression profiling analysis. Differen-
tially expressed miRNAs (DE-miRs) were screened out 
between two sample groups, followed by identification of 
target genes based on bioinformatics methods. Further-
more, functional enrichment analysis was performed for 
the DE-miRs so as to reveal their potential roles in pro-
gression of gastric cancer.
Methods
Sample collections
A total of 10 Tibetan patients (male:female =  6:4) with 
gastric cancer were enrolled in this study. They were 
aged between 33 and 77  years old, and the median age 
was 51.1. The tumor node metastasis stages (TNM) were 
determined basing on the International Union Against 
Cancer and the American Joint Committee on Cancer 
pathological staging systems. The patients were identi-
fied with clinical stages at T2N0M0(1/10), TisN0M0, Tis-
N0M0IIc, TisN0M0IIc, T3N2M0, T3N0M0, T4aN1M0, 
T2N1M0, T3N2M0 or T3N2M0 (Table 1). Matched gas-
tric cancer and adjacent non-cancerous tissue samples 
(n  =  10 in each group) were obtained during surgical 
operation and immediately stored at −80 °C for microar-
ray analysis. All the enrolled patients have given written 
informed consent and the present study was approved 
by Ethics Committee of Qinghai University Affiliated 
Hospital.
Microarray profiling of miRNAs
Total RNA was extracted from the matched cancerous 
and adjacent non-cancerous tissues according to the 
manufacture’ s instructions using RNAiso Plus purchased 
from Treasure Biological Engineering (Dalian, China). 
Reverse transcription-quantitative polymerase chain 
reaction was conducted according to the manufacture’ 
s instructions using a PrimeScript® First Strand cDNA 
Synthesis kit and miRNA qPCR primer mix (Takara Bio, 
Inc, CA, USA). Affymetrix GeneChip microRNA 3.0 
Array (Affymetrix, Inc, Santa, CA, USA) was employed 
for detection of miRNA expression in samples, which 
provides for 100  % miRBase v17 coverage (http://www.
mirbase.org) by a one-color approach.
Differential expression analysis
Raw data of miRNA expression profile from cancerous 
and adjacent non-cancerous tissues were converted into 
recognizable miRNA expression data by RMA (robust 
multi-array analysis) method, followed by median nor-
malization and log2 transformation using Affy package 
(http://www.bioconductor.org/packages/release/bioc/
html/affy.html) in R [14]. During the expression conver-
sion from probe level to miRNA level, the expression 
values of probes corresponding to each miRNA were 
averaged as the miRNA value. Differential expression 
analysis between two groups was analyzed using Limma 
package of R language (http://www.bioconductor.org/
packages/release/bioc/html/limma.html) [15] based on 
the criteria of |log2 FC (fold change)| ≥1 and P value 
<0.05.
Prediction of targets for differentially expressed miRNAs
MultiMiR package (http://multimir.ucdenver.edu/) [16] 
was previously established to predict targets of miRNAs, 
which covered 14 databases including miRecords, miR-
TarBase, TarBase, DIANA-microT, ElMMo, MicroCosm, 
miRanda, miRDB, PicTar, PITA, TargetScan, miR2Dis-
ease, PharmacomiR and PhenomiR. In the present study, 
multiMiR package was employed to predict targets of 
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DE-miRs with the criterion of primary score listed in 
top 35. Meanwhile, only the target genes predicted in at 
least three databases were selected for following analysis. 
Accordingly, the network between targets and DE-miRs 
was constructed using Cytoscape v3.2.1 (http://www.
cytoscape.org/) [17] software.
Functional enrichment analysis for DE‑miRs
Database for Annotation, Visualization and Integrated 
Discovery (DAVID, https://david.ncifcrf.gov/home.jsp) 
[18] is a powerful tool to mine functions of interested 
genes. As miRNAs function through down-regulating 
target genes, to further reveal the potential biological 
functions or pathways that may be changed by the DE-
miRs, the target genes were put into DAVID to screen 
out significantly enriched Kyoto Encyclopedia of Genes 
and Genomes (KEGG, http://www.kegg.jp/) [19] path-
ways and Gene Ontology (GO, http://www.geneontology.
org) [20] biological processes. The selection criterion for 
significant GO and KEGG pathway terms was P value 
<0.05.
Results
DE‑miRs between gastric cancer and adjacent 
non‑cancerous samples
By using Limma package in R with the criteria of |log2 
FC| ≥1 and P value <0.05, a total of 27 DE-miRs in gas-
tric cancer were screened out, including 25 down-regu-
lated miRNAs (e.g. hsa-miR-148a-3p, hsa-miR-148b-3p 
and hsa-miR-363-3p) and 2 up-regulated miRNAs (hsa-
miR-196b-3p and hsa-miR-138-1-3p) (Table 2). The heap 
map of DE-miRs was shown in Fig. 1.
Table 1 Information on sample cases
HP Helicobacter pylori
Number Age Sex Elevation (m) Staging HP infection Pathological description
B1 299295 46 Male 2260 T2N0M0(1/10) High-differentiated adenocarcinoma invaded submucosa, lymph 
node 0/10
B2 302629 38 Female 2850 TisN0M0 Intramucosal carcinoma in gastric antrum (0/11)
B3 WJ 57 Male 2840 T4aN1M0 Distal gastric carcinoma, tumor invaded full thickness and vascular 
nerves (+) 2/15, low and median differentiated adenocarcinoma
B5 211409 56 Male 2850 TisN0M0IIc
B6 49 Male 2050 TisN0M0IIc Intramucosal carcinoma
A1 303135 43 Male 3280 T3N2M0 Low differentiated tubular adenocarcinoma invaded deep muscle 
layer (6/9), vascular and nerve (+)
A2 302628 33 Male 3860 T3N0M0 Ulcer tubular well-differentiated adenocarcinoma invaded the deep 
muscularis serosa, vascular nerve (+), 0/13
A3 WJ 56 Female 3800 T2N1M0 HP−, gastroscope Distal gastric cancer
A4 WJ 77 Female 4800 T3N2M0 HP+, gastroscope Gastric carcinoma
A6 300804 56 Male 3100 T3N2M0 Differentiated tubular adenocarcinoma invaded deep muscularis, 
vascular+, nerve+
Table 2 The 27 differentially expressed microRNAs in gas-
tric cancer
Log fold change >0, up-regulated; log fold change <0, down-regulated
Accession MicroRNAs Log fold change P value
MIMAT0000243 hsa-miR-148a-3p −1.8142778 0.006134223
MIMAT0027583 hsa-miR-6840-3p −1.47970911 0.015759083
MIMAT0027464 hsa-miR-6782-5p −1.45651738 0.018393456
MIMAT0000759 hsa-miR-148b-3p −1.43506791 0.010053602
MIMAT0028117 hsa-miR-7110-5p −1.43359191 0.038837699
MIMAT0000707 hsa-miR-363-3p −1.3662862 0.049770472
MIMAT0018352 hsa-miR-3937 −1.32835296 0.023596283
MIMAT0004694 hsa-miR-342-5p −1.27792593 0.044159324
MIMAT0022721 hsa-miR-1247-3p −1.17878373 0.020578891
MIMAT0019077 hsa-miR-1587 −1.1697371 0.048251207
MIMAT0016882 hsa-miR-4253 −1.15418525 0.017333874
MIMAT0027474 hsa-miR-6787-5p −1.14471871 0.040401132
MIMAT0015070 hsa-miR-3188 −1.10659872 0.042107841
MIMAT0025844 hsa-miR-6716-5p −1.08787366 0.019653906
MIMAT0019033 hsa-miR-4498 −1.08655973 0.018678343
MIMAT0004948 hsa-miR-885-3p −1.0692305 0.044870796
MIMAT0018986 hsa-miR-4462 −1.0690462 0.004846197
MIMAT0028211 hsa-miR-7150 −1.06220727 0.040895785
MIMAT0027408 hsa-miR-6754-5p −1.03580421 0.022410575
MIMAT0021128 hsa-miR-5196-5p −1.0324015 0.035802131
MIMAT0020601 hsa-miR-1273f −1.02885192 0.031420972
MIMAT0022260 hsa-miR-5572 −1.02726895 0.033720698
MIMAT0021120 hsa-miR-5189-5p −1.01814356 0.020114063
MIMAT0027548 hsa-miR-6824-5p −1.01710815 0.020467938
MIMAT0031016 hsa-miR-8089 −1.01329602 0.021980497
MIMAT0009201 hsa-miR-196b-3p 1.33573282 0.048038696
MIMAT0004607 hsa-miR-138-1-3p 1.405280355 0.023694469
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Analysis of network of miRNAs‑targets
According to multiMiR package, a number of 1445 tar-
get genes of 13 DE-miRs were screened out. Based on the 
aforementioned criterion, the network of miRNA-target 
was constructed using Cytoscape (Fig. 2). In the network, 
hsa-miR-148a-3p, hsa-miR-148b-3p and hsa-miR-363-3p 
were identified with the most target genes, and further-
more, the three miRNAs targeted numerous common 
genes such as CAND1 (cullin-associated and neddyla-
tion-dissociated 1), KLF4 (Kruppel-like factor 4), S1PR1 
(sphingosine-1-phosphate receptor 1), Wnt1 (wingless-
type MMTV integration site family, member 1), CNTN4 
(contactin 4) and BCL2L11 [BCL2-like 11 (apoptosis 
facilitator)].
Functional and pathways of DE‑miRs
KEGG pathway and GO functional enrichment analy-
sis indicated that only three miRNAs (hsa-miR-148a-3p, 
hsa-miR-148b-3p and hsa-miR-363-3p) were significantly 
enriched in numerous common KEGG pathways and GO 
biological processes (P < 0.05, Additional file 1: Table S1). 
Among those significant pathways, some known cancer-
related pathways were screened out, including “pathway 
in cancer”, “Wnt signaling pathway”, “MAPK signaling 
pathway” and “Jak-STAT signaling pathway” (Fig. 3).
Discussion
MiRNAs exert regulatory effects on gene expression 
in humans, resulting in cell growth, differentiation and 
apoptosis via down-regulating target genes in cancer [21]. 
In the present study, a total of 27 DE-miRs were screened 
out, including hsa-miR-148a-3p, hsa-miR-148b-3p and 
hsa-miR-363-3p, which targeted the most genes. Further-
more, the three miRNAs were significantly enriched in 
cancer-related pathways, including Wnt signaling path-
way, MAPK (mitogen-activated protein kinase) signaling 
Fig. 1 Heat map of differentially expressed microRNAs. Red represents up-regulation and green represents down-regulation
Page 5 of 8Luo et al. Cancer Cell Int  (2015) 15:115 
pathway and Jak-STAT (Janus kinase-signal transducer 
and activator of transcription) signaling pathway.
Wnt signaling pathway is implicated in cancer devel-
opment and its hyperactivation can lead to enhanced 
tumorigenicity and increased metastatic potential [22]. 
In gastric cancer, overexpressed miR-544a is demon-
strated to activate WNT signaling pathway which further 
contributes to the disease progression [13]. In the pre-
sent study, we identified that hsa-miR-148a-3p, hsa-miR-
148b-3p and hsa-miR-363-3p were remarkably enriched 
in Wnt signaling pathway. Reportedly, miR-148a inhibits 
the metastasis of hepatocellular carcinoma via acting on 
Wnt signaling pathway [23]. MiR-363 down-regulates 
the expression of myeloid cell leukemia-1 [24] whose 
expression correlates with phosphorylated glycogen syn-
thase kinase-3beta, the key component of Wnt signaling 
pathway in breast cancer [25]. Notably, the above miRNA 
targets, such as Wnt1, were significantly enriched in Wnt 
signaling pathway. We can speculate that the miR-148a, 
miR-148b and miR-363 may play significant roles in 
Fig. 2 Network of differentially expressed microRNAs-target genes. Circle represents target genes and diamond represents microRNAs. Red repre-
sents up-regulation and green represents down-regulation
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gastric cancer progression via regulating the Wnt signal-
ing pathway.
Besides, MAPK signaling pathway is dysregulated in 
gastric cancer, leading to abnormal cell proliferation and 
metastasis [26]. Moreover, the signaling pathway is impli-
cated in drug resistance in gastric cancer by regulating 
the expression of apoptotic proteins Bax (BCL2-associ-
ated X protein)/Bcl-2 (B-cell CLL/lymphoma 2) [27]. Our 
enrichment analysis showed that hsa-miR-148a-3p, hsa-
miR-148b-3p and hsa-miR-363-3p were also significantly 
enriched in MAPK signaling pathway. In breast cancer, 
miR-148a acts as a tumor suppressor via targeting IGF-IR 
(insulin-like growth factor-I receptor) and IRS1 (insulin 
receptor substrate 1) and further suppressing the down-
stream MAPK signaling pathway [28]. Besides, miR-363 
is found to be down-regulated in gastric cancer and its 
down-regulation is associated with tumor differentiation, 
TNM stage and lymph-node metastasis [29]. Notably, the 
suppression of their common target KLF4 could inhibit 
the expression of various Erk5 (mitogen-activated protein 
kinase 7) targets and further affect the MAPK cascade 
in the regulation of endothelial integrity in cancer [30]. 
The enrichment of miR-148a, miR-148b and miR-363 in 
MAPK signaling pathway may suggest a joint contribu-
tion to gastric cancer development via involving MAPK 
signaling pathway.
Additionally, hsa-miR-148a-3p, hsa-miR-148b-3p and 
hsa-miR-363-3p were found to be dramatically enriched 
in Jak-STAT signaling pathway. Jak-STAT serves as a 
straightforward mechanism whereby cells sense environ-
mental cures and further regulate cell growth and dif-
ferentiation in cancer [31]. The inhibition of Jak-STAT 
signaling pathway can lead to decreased cell proliferation 
and enhanced cell apoptosis in gastric cancer cells [32]. 
Exogenous miR-363 promotes cell growth, progression 
and tumorsphere formation of SC-M1 gastric cancer 
cells, and the knockdown of miR-363 suppresses tumo-
rigenesis of SC-M1 cells [33]. MiR-148a/b is dysregu-
lated and their haplotype is significantly correlated with 
gastric cancer [34]. S1PR1, one of the common targets 
Fig. 3 Network of functional enrichment results of differentially expressed microRNAs. V-shape represents microRNA and rectangle represents 
significant pathways enriched by target genes of microRNAs
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of miR-148a-3p, -148b-3p and -363-3p, is implicated 
in NFκB/IL-6/STAT3/S1PR1 amplification loop that is 
important for chronic colitis-related cancer and can be 
suggested as therapeutic option [35]. The enrichment of 
the three miRNAs in Jak-STAT signaling pathway implies 
their involvement in gastric cancer progression via Jak-
STAT signaling pathway.
We should note that there were some limitations in the 
present study. Herein, although we demonstrated a sig-
nificant enrichment of dysregulated hsa-miR-148a-3p, 
hsa-miR-148b-3p and hsa-miR-363-3p in cancer-related 
pathways in patients with gastric cancer, we did not fur-
ther validate their expressions, nor demonstrate their 
roles in cancer-related pathways using systematically 
functional experiments. Moreover, as there are only 10 
samples enrolled in this study, we did not further con-
sider the DE-miRs among different stages. Besides, the 
present results were just obtained based on microarray 
analysis and bioinformatics prediction, and needed to be 
further validated in future. However, this study can be 
regarded as a preliminary study and to an extent provide 
some valuable directions for future studies, especially for 
researches on gastric cancer in Tibetan.
In summary, the present study identified a downregu-
lation of hsa-miR-148a-3p, hsa-miR-148b-3p and hsa-
miR-363-3p in gastric cancer in Tibetan using microarray 
analysis. What is more, we demonstrated their significant 
enrichment in cancer-related pathways, including Wnt 
signaling pathway, MAPK signaling pathway and Jak-
STAT signaling pathway. These findings suggested the 
potential usage of hsa-miR-148a-3p, hsa-miR-148b-3p 
and hsa-miR-363-3p as diagnostic and therapeutic bio-
markers for gastric cancer-infected Tibetan. However, 
further experimental validations are in urgent need to 
confirm these results.
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